

## Special Issue

# Pathology, Complications and Prognosis of Type 1 Diabetes

### Message from the Guest Editor

This Special Issue, *Pathology, Complications and Prognosis of Type 1 Diabetes*, offers a comprehensive and up-to-date synthesis of current knowledge on the complex pathophysiology and clinical evolution of type 1 diabetes mellitus (T1DM), an autoimmune condition resulting in the progressive destruction of pancreatic  $\beta$ -cells. The contributions gathered in this issue address the key mechanisms involved in disease initiation and progression, including genetic susceptibility, environmental factors, and immune-mediated processes. A particular focus is placed on the spectrum of complications—both acute, such as diabetic ketoacidosis, and chronic, including microvascular (retinopathy, nephropathy, neuropathy) and macrovascular damage. The prognostic implications of variables such as age at onset, metabolic control, and disease duration are critically discussed, alongside emerging biomarkers and therapeutic approaches. Integrating clinical experience with advances in translational research, the articles aim to provide a multidimensional understanding of T1DM.

### Guest Editor

Dr. Maurizio Delvecchio

Department of Biotechnological and Applied Clinical Sciences,  
University of L'Aquila, 67100 L'Aquila, Italy

### Deadline for manuscript submissions

27 February 2026



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/244776](https://mdpi.com/si/244776)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).